Epstein-Barr Virus-Associated Lymphoproliferative Disorders

Reviews in Clinical and Experimental Hematology

Volumn 7, Issue 4, 2003, Pages 362-374

  Ambinder, Richard F ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CELL PROTEIN; VIRUS PROTEIN;

BURKITT LYMPHOMA; CELL DEATH; CELL PROLIFERATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HERPES VIRUS; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSURVEILLANCE; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; NATURAL KILLER CELL; NONHUMAN; REVIEW; T CELL LYMPHOMA; T LYMPHOCYTE; VIRUS GENE;

ADULT; CELL TRANSFORMATION, VIRAL; CHILD; DISEASE SUSCEPTIBILITY; EPSTEIN-BARR VIRUS INFECTIONS; FORECASTING; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOLOGIC DEFICIENCY SYNDROMES; LYMPHOCYTE SUBSETS; LYMPHOMA; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION IMMUNOLOGY;

EID: 1342346705     PISSN: 11270020     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Epstein MA. Reflections on Epstein-Barr virus: some recently resolved old uncertainties. J Infect, 43: 111-115, 2001.
2. Young LS, Finerty S, Brooks L, et al. Epstein-Barr virus gene expression in malignant lymphomas induced by experimental virus infection of cottontop tamarins. J Virol, 63: 1967-1974, 1989.
3. Cho Y, Ramer J, Rivailler P, et al. An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc Natl Acad Sci USA, 98: 1224-1229, 2001.
4. Wilson AD, Lovgren-Bengtsson K, Villacres-Ericsson M, et al. The major Epstein-Barr virus (EBV) envelope glycoprotein gp340 when incorporated into Iscoms primes cytotoxic T-cell responses directed against EBV lymphoblastoid cell lines. Vaccine, 17: 1282-1290, 1999.
5. Rowe M, Young LS, Crocker J, et al. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med, 173: 147-158, 1991.
6. Mosier DE. Viral pathogenesis in hu-PBL-SCID mice. Semin Immunol, 8: 255-62, 1996.
7. Cohen JI. Epstein-Barr virus infection. N Engl J Med, 343: 481-492, 2000.
8. Karajannis MA, Hummel M, Anagnostopoulos I, et al. Strict lymphotropism of Epstein-Barr virus during acute infectious mononucleosis in nonimmunocompromised individuals. Blood, 89: 2856-2862, 1997.
9. Kuppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol, 3: 801-812, 2003.
10. Ryon JJ, Hayward SD, MacMahon EM, et al. In situ detection of lytic Epstein-Barr virus infection: expression of the NotI early gene and viral interleukin-10 late gene in clinical specimens. J Infect Dis, 168: 345-351, 1993.
11. Hislop AD, Annels NE, Gudgeon NH, et al. Epitope-specific evolution of human CD8(+) T cell responses from primary to persistent phases of Epstein-Barr virus infection. J Exp Med, 195: 893-905, 2002.
12. Miyashita EM, Yang B, Babcock GJ, et al. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell. J Virol, 71: 4882-4891, 1997.
13. Tierney RJ, Steven N, Young LS, et al. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol, 68: 7374-7385, 1994.
14. Yang J, Tao Q, Flinn IW, et al. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical response. Blood, 96: 4055-4063, 2000.
15. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol, 1: 75-82, 2001.
16. Moore SM, Cannon JS, Tanhehco YC, et al. Induction of Epstein-Barr virus kinases to sensitize tumor cells to nucleoside analogues. Antimicrob Agents Chemother, 45: 2082-2091, 2001.
17. Yao QY, Ogan P, Rowe M, et al. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers. Int J Cancer, 43: 67-71, 1989.
18. Kieff E and Rickinson AB. Epstein-Barr virus and its replication. In: Fields Virology. Fields BN, Knipe DM, Howley PM, et al. (eds). Lippincott Williams & Wilkins, Philadelphia, pp. 2511-2573, 2001.
19. Lee JM, Lee KH, Weidner M, et al. Epstein-Barr virus EBNA2 blocks Nur77-mediated apoptosis. Proc Natl Acad Sci USA, 99: 11878-11883, 2002.
20. Lam N and Sugden B. CD40 and its viral mimic, LMP1: similar means to different ends. Cell Signal, 15: 9-16, 2003.
21. Uchida J, Yasui T, Takaoka-Shichijo Y, et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science, 286: 300-303, 1999.
22. Bishop GA and Busch LK. Molecular mechanisms of B-lymphocyte transformation by Epstein-Barr virus. Microbes Infect, 4: 853-857, 2002.
23. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell, 43: 831-840, 1985.
24. Wu H, Kapoor P, Frappier L. Separation of the DNA replication, segregation, and transcriptional activation functions of Epstein-Barr nuclear antigen 1. J Virol, 76: 2480-2490, 2002.
25. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J, 15: 3117-3126, 1996.
26. Tsimbouri P, Drotar ME, Coy JL, et al. bcl-xL and RAG genes are induced and the response to IL-2 enhanced in EmuEBNA-1 transgenic mouse lymphocytes. Oncogene, 21: 5182-5187, 2002.
27. Kang MS, Hung SC, Kieff E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc Natl Acad Sci USA, 98: 15233-15238, 2001.
28. Caldwell RG, Wilson JB, Anderson SJ, et al. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity, 9: 405-411, 1998.
29. Portis T, Dyck P, Longnecker R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin's lymphoma. Blood, 102: 4166-4178, 2003.
30. Bellows DS, Howell M, Pearson C, et al. Epstein-Barr virus BALF1 is a BCL-2-like antagonist of the herpesvirus antiapoptotic BCL-2 proteins. J Virol, 76: 2469-2479, 2002.
31. Tao Q, Robertson KD, Manns A, et al. Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: molecular analysis of primary tumor tissue. Blood, 91: 1373-1381, 1998.
32. Niedobitek G, Agathanggelou A, Rowe M, et al. Heterogeneous expression of Epstein-Barr virus latent proteins in endemic Burkitt's lymphoma. Blood, 86: 659-665, 1995.
33. Komano J, Maruo S, Kurozumi K, et al. Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol, 73: 9827-9831, 1999.
34. Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol, 72: 9150-9156, 1998.
35. Pajic A, Staege MS, Dudziak D, et al. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int J Cancer, 93: 810-816, 2001.
36. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med, 8: 1098-1104, 2002.
37. Khanna R, Burrows SR, Suhrbier A, et al. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J Immunol, 150: 5154-5162, 1993.
38. Rao CR, Gutierrez MI, Bhatia K, et al. Association of Burkitt's lymphoma with the Epstein-Barr virus in two developing countries. Leuk Lymphoma, 39: 329-337, 2000.
39. Sandlund JT, Gorban ZI, Berard CW, et al. Large proportion of Epstein-Barr virus-associated small noncleaved cell lymphomas among children with non-Hodgkin's lymphoma at a single institution in Moscow, Russia. Am J Clin Oncol, 22: 523-525, 1999.
40. Srinivas SK, Sample JT, Sixbey JW. Spontaneous loss of viral episomes accompanying Epstein-Barr virus reactivation in a Burkitt's lymphoma cell line. J Infect Dis, 177: 1705-1709, 1998.
41. Razzouk BI, Srinivas S, Sample CE, et al. Epstein-Barr Virus DNA recombination and loss in sporadic Burkitt's lymphoma. J Infect Dis, 173: 529-535, 1996.
42. Subar M, Neri A, Inghirami G, et al. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. Blood, 72: 667-671, 1988.
43. Chan JK, Yip TT, Tsang WY, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol, 18: 938-946, 1994.
44. Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood, 89: 4501-4513, 1997.
45. Arber DA, Weiss LM, Albujar PF, et al. Nasal lymphomas in Peru. High incidence of T-cell immunophenotype and Epstein-Barr virus infection. Am J Surg Pathol, 17: 392-369, 1993.
46. Elenitoba-Johnson KS, Zarate-Osorno A, Meneses A, et al. Cytotoxic granular protein expression, Epstein-Barr virus strain type, and latent membrane protein-1 oncogene deletions in nasal T-lymphocyte/natural killer cell lymphomas from Mexico. Mod Pathol, 11: 754-761, 1998.
47. Gutierrez MI, Spangler G, Kingma D, et al. Epstein-Barr virus in nasal lymphomas contains multiple ongoing mutations in the EBNA-1 gene. Blood, 92: 600-606, 1998.
48. Quintanilla-Martinez L, Franklin JL, Guerrero I, et al. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: high prevalence of p53 overexpression. Hum Pathol, 30: 849-855, 1999.
49. Jaffe ES, Krenacs L, Kumar S, et al. Extranodal peripheral T-cell and NK-cell neoplasms. Am J Clin Pathol, 111: S46-55, 1999.
50. Chiang AK, Tao Q, Srivastava G, et al. Nasal NK- and T-cell lymphomas share the same type of Epstein-Barr virus latency as nasopharyngeal carcinoma and Hodgkin's disease. Int J Cancer, 68: 285-290, 1996.
51. Gelb AB, van de Rijn M, Regula DP Jr., et al. Epstein-Barr virus-associated natural killer-large granular lymphocyte leukemia. Hum Pathol, 25: 953-960, 1994.
52. Kawa-Ha K, Ishihara S, Ninomiya T, et al. CD3-negative lymphoproliferative disease of granular lymphocytes containing Epstein-Barr viral DNA. J Clin Invest, 84: 51-55, 1989.
53. Hart DN, Baker BW, Inglis MJ, et al. Epstein-Barr viral DNA in acute large granular lymphocyte (natural killer) leukemic cells. Blood, 79: 2116-2123, 1992.
54. Anagnostopoulos I, Hummel M, Stein H. Frequent presence of latent Epstein-Barr virus infection in peripheral T cell lymphomas. A review. Leuk Lymphoma, 19: 1-12, 1995.
55. Brauninger A, Spieker T, Willenbrock K, et al. Survival and clonal expansion of mutating "forbidden" (immunoglobulin receptor-deficient) epstein-barr virus-infected b cells in angioimmunoblastic t cell lymphoma. J Exp Med, 194: 927-940, 2001.
56. Beaty MW, Toro J, Sorbara L, et al. Cutaneous lymphomatoid granulomatosis: correlation of clinical and biologic features. Am J Surg Pathol, 25: 1111-1120, 2001.
57. Filipovich AH MA, Robison L, et al. Lymphoproliferative disorders associated with primary immunodeficiencies. In: The non-Hodgkin's lymphomas. Margath I. Oxford University Press, London, pp. 459-471, 1995.
58. Harrington DS, Weisenburger DD, Purtilo DT. Malignant lymphoma in the X-linked lymphoproliferative syndrome. Cancer, 59: 1419-1429, 1987.
59. Morra M, Howie D, Grande MS, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol, 19: 657-682, 2001.
60. Strahm B, Rittweiler K, Duffner U, et al. Recurrent B-cell non-Hodgkin's lymphoma in two brothers with X-linked lymphoproliferative disease without evidence for Epstein-Barr virus infection. Br J Haematol, 108: 377-382, 2000.
61. Williams LL, Rooney CM, Conley ME, et al. Correction of Duncan's syndrome by allogeneic bone marrow transplantation. Lancet, 342: 587-588, 1993.
62. Gerritsen EJ, Stam ED, Hermans J, et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant, 18: 377-382, 1996.
63. Jabado N, Le Deist F, Cant A, et al. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Pediatrics, 98: 420-428, 1996.
64. Martin PJ, Shulman HM, Schubach WH, et al. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med, 101: 310-315, 1984.
65. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood, 99: 3909-3915, 2002.
66. Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood, 71: 1234-1243, 1988.
67. Swinnen LJ. Organ transplant-related lymphoma. Curr Treat Options Oncol, 2: 301-308, 2001.
68. Witherspoon RP, Fisher LD, Schoch G, et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med, 321: 784-789, 1989.
69. Zutter MM, Martin PJ, Sale GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood, 72: 520-529, 1988.
70. Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood, 87: 4531-4537, 1996.
71. Cesarman E, Chadburn A, Liu YF, et al. BCL-6 gene mutations in posttransplantation lymphoproliferative disorders predict response to therapy and clinical outcome. Blood, 92: 2294-2302, 1998.
72. Knowles DM, Cesarman E, Chadburn A, et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood, 85: 552-565, 1995.
73. Harris NL, Ferry JA, Swerdlow SH. Posttransplant lymphoproliferative disorders: summary of Society for Hematopathology Workshop. Semin Diagn Pathol, 14: 8-14, 1997.
74. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol, 14: 2-7, 1997.
75. MacMahon EM, Glass JD, Hayward SD, et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. Lancet, 338: 969-973, 1991.
76. Camilleri-Broet S, Davi F, Feuillard J, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol, 28: 367-374, 1997.
77. Cingolani A, Gastaldi R, Fassone L, et al. Epstein-Barr virus infection is predictive of CNS involvement in systemic AIDS-related non-Hodgkin's lymphomas. J Clin Oncol, 18: 3325-3330, 2000.
78. Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol, 167: 381-384, 1992.
79. Siebert JD, Ambinder RF, Napoli VM, et al. Human immunodeficiency virus-associated Hodgkin's disease contains latent, not replicative, Epstein-Barr virus. Hum Pathol, 26: 1191-1195, 1995.
80. Tirelli U, Serraino D, Spina M, et al. Epstein-Barr virus-encoded latent membrane protein-1 expression as prognostic factor in AIDS-related non-Hodgkin's lymphoma. Aids, 9: 99-100, 1995.
81. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/-human herpesvirus-8. Blood, 90: 1186-1191, 1997.
82. Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol, 12: 200-217, 1999.
83. Hjalgrim H, Askling J, Rostgaard K, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med, 349: 1324-1332, 2003.
84. Alexander FE, Lawrence DJ, Freeland J, et al. An epidemiologic study of index and family infectious mononucleosis and adult Hodgkin's disease (HD): evidence for a specific association with EBV+ve HD in young adults. Int J Cancer, 107: 298-302, 2003.
85. Glaser SL, Lin RJ, Stewart SL, et al. Epstein-Barr virus-associated Hodgkin's disease: epidemiologic characteristics in international data. Int J Cancer, 70: 375-82, 1997.
86. Ambinder RF, Browning PJ, Lorenzana I, et al. Epstein-Barr virus and childhood Hodgkin's disease in Honduras and the United States. Blood, 81: 462-467, 1993.
87. Chang KL, Albujar PF, Chen YY, et al. High prevalence of Epstein-Barr virus in the Reed-Sternberg cells of Hodgkin's disease occurring in Peru. Blood, 81: 496-501, 1993.
88. Glaser SL, Clarke CA, Gulley ML, et al. Population-based patterns of human immunodeficiency virus-related Hodgkin lymphoma in the Greater San Francisco Bay Area, 1988-1998. Cancer, 98: 300-309, 2003.
89. Reiman A, Powell JE, Flavell KJ, et al. Seasonal differences in the onset of the EBV-positive and -negative forms of paediatric Hodgkin's lymphoma. Br J Cancer, 89: 1200-1201, 2003.
90. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res, 84: 277-312, 2002.
91. Merchant M, Caldwell RG, Longnecker R. The LMP2A ITAM is essential for providing B cells with development and survival signals in vivo. J Virol, 74: 9115-9124, 2000.
92. Murray PG, Constandinou CM, Crocker J, et al. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood, 92: 2477-2483, 1998.
93. Clarke CA, Glaser SL, Dorfman RF, et al. Epstein-Barr virus and survival after Hodgkin disease in a population-based series of women. Cancer, 91: 1579-1587, 2001.
94. Flavell KJ, Billingham LJ, Biddulph JP, et al. The effect of Epstein-Barr virus status on outcome in age- and sex-defined subgroups of patients with advanced Hodgkin's disease. Ann Oncol, 14: 282-290, 2003.
95. Lechowicz MJ, Lin L, Ambinder RE Epstein-Barr virus DNA in body fluids. Curr Opin Oncol, 14: 533-537, 2002.
96. Antinori A, De Rossi G, Ammassari A, et al. Value of combined approach with thallium-201 single-photon emission computed tomography and Epstein-Barr virus DNA polymerase chain reaction in CSF for the diagnosis of AIDS-related primary CNS lymphoma. J Clin Oncol, 17: 554-560, 1999.
97. Holmes RD, Orban-Eller K, Karrer FR, et al. Response of elevated Epstein-Barr virus DNA levels to therapeutic changes in pediatric liver transplant patients: 56-month follow up and outcome. Transplantation, 74: 367-372, 2002.
98. Rose C, Green M, Webber S, et al. Detection of Epstein-Barr virus genomes in peripheral blood B cells from solid-organ transplant recipients by fluorescence in situ hybridization. J Clin Microbiol, 40: 2533-2544, 2002.
99. Lei KI, Chan LY, Chan WY, et al. Diagnostic and prognostic implications of circulating cell-free Epstein-Barr virus DNA in natural killer/T-cell lymphoma. Clin Cancer Res, 8: 29-34, 2002.
100. Wagner HJ, Rooney CM, Heslop HE. Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 8: 1-8, 2002.